MED12 mutation in patients with hysteromyoma

Ye,Jun; Wang,Hua; Chen,Ya‑Bao; Yuan,Dong‑Lan; Zhang,Li‑Xin; Liu,Lin

doi:10.3892/ol.2015.3118

June-2015 Volume 9 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2015 Volume 9 Issue 6

Full Size Image

Article

MED12 mutation in patients with hysteromyoma

Authors:
- Jun Ye
- Hua Wang
- Ya‑Bao Chen
- Dong‑Lan Yuan
- Li‑Xin Zhang
- Lin Liu
View Affiliations / Copyright

Affiliations: Department of Laboratory Medicine, Taizhou People's Hospital, Taizhou, Jiangsu 225300, P.R. China
Pages: 2771-2774
|
Published online on: April 15, 2015

https://doi.org/10.3892/ol.2015.3118
Expand metrics +

Abstract

Mediator Complex Subunit 12 (MED12) is a subunit of the mediator complex, which is believed to regulate global, as well as gene‑specific, transcription. It has been reported that MED12 is mutated at high frequency in hysteromyoma. Recent studies have also shown that MED12 presents with different mutation frequencies in hysteromyoma patients of different populations. However, there are few studies with regard to the MED12 gene mutation in hysteromyoma patients in the Chinese Han population. In the present study, the MED12 mutations of 171 patients with hysteromyoma were analyzed; the results showed that 93 patients exhibited different MED12 mutations, including 131G→T, 131G→A, 130G→A, 146C→T, 130G→A, 130G→C, 128A→C, 130G→T, 127Ins27, 118_132Del15, 117_134Del18, 131_148Del18 and 141_165Del15. The mutation frequency was similar to that found in individuals of African descent or individuals of other non-Caucasian ethnicities, and lower than that in the Finnish or North American populations. Further analysis of 141 patients whose hysteromyoma was measured showed that the mutation frequency of MED12 in patients with large hysteromyomas was significantly lower than that in those with small hysteromyomas. These results suggested that MED12 mutation was important in the development of hysteromyomas in the Chinese Han population and that the size of the hysteromyoma may negatively correlate with the mutation frequency of MED12. This study supplemented current information on MED12 mutations in different races and may aid in developing personalized diagnoses for patients with hysteromyoma in the future.

View Figures

View References

1	Okolo S: Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 22:571–588. 2008. View Article : Google Scholar : PubMed/NCBI
2	Shi YF: Incidence, aetiology of uterine fibroids. Zhongguo Yi Kan. 37:11122002.(In Chinese).
3	Stewart EA: Uterine fibroids. Lancet. 357:293–298. 2001. View Article : Google Scholar : PubMed/NCBI
4	Flynn M, Jamison M, Datta S and Myers E: Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol. 195:955–964. 2006. View Article : Google Scholar : PubMed/NCBI
5	Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J and Stang P: Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol. 108:930–937. 2006. View Article : Google Scholar : PubMed/NCBI
6	Taatjes DJ: The human Mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci. 35:315–322. 2010. View Article : Google Scholar : PubMed/NCBI
7	Makinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM and Aaltonen LA: Med12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget. 2:966–969. 2011.PubMed/NCBI
8	Makinen N, Mehine M, Tolvanen J, et al: Med12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 334:252–255. 2011. View Article : Google Scholar : PubMed/NCBI
9	McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U and Rajkovic A: Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One. 7:e332512012. View Article : Google Scholar : PubMed/NCBI
10	Guidelines for Ethical Review Work of Drug Clinical Trials 2010. China Food and Drug Administration; Beijing: pp. 1–15. 2010
11	Kjerulff KH, Langenberg P, Seidman JD, Stolley PD and Guzinski GM: Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med. 41:483–490. 1996.PubMed/NCBI
12	Marshall LM, Spiegelman D, Barbieri RL, et al: Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 90:967–973. 1997. View Article : Google Scholar : PubMed/NCBI
13	Baird DD, Dunson DB, Hill MC, Cousins D and Schectman JM: High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 188:100–107. 2003. View Article : Google Scholar : PubMed/NCBI
14	Wise LA, Palmer JR, Harlow BL, et al: Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Hum Reprod. 19:1746–1754. 2004. View Article : Google Scholar : PubMed/NCBI
15	Huyck KL, Panhuysen CI, Cuenco KT, et al: The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol. 198:168.e1–168.e9. 2008. View Article : Google Scholar
16	Templeman C, Marshall SF, Clarke CA, et al: Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril. 92:1436–1446. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wise LA, Palmer JR, Spiegelman D, Harlow BL, Stewart EA, Adams-Campbell LL and Rosenberq L: Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. Epidemiology. 16:346–354. 2005. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

MED12 mutation in patients with hysteromyoma

This article is mentioned in:

Abstract

Figure 1

Related Articles